ArticleNuclear medicine and molecular imaging2019
Eruption of Metastatic Paraganglioma After Successful Therapy with
Article in Nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00004847 (Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- Radioresistant mouse pheochromocytoma cell lines.Frontiers in oncology · 2025Article
- Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.The Journal of clinical endocrinology and metabolism · 2024Review
- Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.PloS one · 2024Article
- Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics · 2024Review
- The heterobivalent (SSTR2/albumin) radioligand [Theranostics · 2024Article
- Article
- Case Report: Octreotide plus CVD chemotherapy for the treatment of multiple metastatic paragangliomas after double resection for functional bladder paraganglioma and urothelial papilloma.Frontiers in oncology · 2022Article
- Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [Intractable & rare diseases research · 2021Article
- HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.Cancers · 2021Article
- Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.Frontiers in endocrinology · 2021Review
- Targeted Radionuclide Therapy in Patient-Derived Xenografts UsingMolecular cancer therapeutics · 2020Article
- Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.Endocrine-related cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractMetastatic paraganglioma treatment options are limited. Peptide receptor radionuclide therapy (PRRT) has been introduced as a novel management option for metastatic neuroendocrine tumors demonstrating safety, efficacy, and increased quality of life. We present two cases of marked progression of metastatic paraganglioma following initial partial response to PRRT. Given their positivity on CLINICALTRIALSGOV IDENTIFIER: NCT00004847.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.